📊 BHVN Key Takeaways
Is Biohaven Ltd. (BHVN) a Good Investment?
Pre-revenue pharmaceutical company with severe operating losses (-$130.4M) and no revenue generation, indicating early-stage development status. While maintaining strong liquidity ($273.1M cash, 7.41x current ratio) and zero debt provide ~1.8 year operational runway, the company is destroying shareholder value with negative ROE of -100.8% and ROA of -28.0%.
Biohaven's fundamentals remain very weak: it is generating no reported revenue while posting a $738.82M net loss and burning more than $609M in operating cash flow. Although losses improved year over year and liquidity is currently adequate with $229.96M of cash and a 3.18x current ratio, the business still lacks evidence of durable operating leverage, self-funded growth, or a sustainable profitability path.
Biohaven Ltd. Key Strengths (BHVN)
- Strong cash position of $273.1M representing 58% of total assets
- Excellent liquidity with 7.41x current ratio and no long-term debt obligations
- Zero leverage (0.00 debt/equity) provides financial flexibility for operations and future financing
- Loss per share and net loss improved year over year, indicating some operating progress
- Balance sheet leverage appears low with no reported long-term debt and 0.00x debt-to-equity
- Current liquidity is solid, supported by $229.96M in cash and a 3.18x current ratio
BHVN Stock Risks: Biohaven Ltd. Investment Risks
- Absent revenue generation with no sales reported despite pharmaceutical sector classification
- Operating cash burn of -$149.9M annually provides approximately 1.8 year runway at current rate
- Persistent negative profitability destroying shareholder equity with -100.8% ROE and -28.0% ROA
- No reported revenue means the business is not yet demonstrating commercial traction or recurring earnings power
- Extremely high cash burn and deeply negative operating income suggest future capital needs if spending remains elevated
- Very small equity base and highly negative ROE/ROA reflect weak financial resilience and poor capital efficiency
Key Metrics to Watch
- Clinical trial progression and FDA approval timeline for pipeline candidates
- Quarterly operating cash burn trajectory to assess runway extension or compression
- Revenue realization date and initial sales volumes from approved indications
- Quarterly revenue emergence and commercialization progress
- Operating cash burn relative to cash balance and equity cushion
Biohaven Ltd. (BHVN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.41x current ratio provides a solid financial cushion.
BHVN Profit Margin, ROE & Profitability Analysis
BHVN vs Healthcare Sector: How Biohaven Ltd. Compares
How Biohaven Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biohaven Ltd. Stock Overvalued? BHVN Valuation Analysis 2026
Based on fundamental analysis, Biohaven Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biohaven Ltd. Balance Sheet: BHVN Debt, Cash & Liquidity
BHVN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biohaven Ltd.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.73 indicates the company is currently unprofitable.
BHVN Revenue Growth, EPS Growth & YoY Performance
Biohaven Ltd. Dividends, Buybacks & Capital Allocation
BHVN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biohaven Ltd. (CIK: 0001935979)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BHVN
What is the AI rating for BHVN?
Biohaven Ltd. (BHVN) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BHVN's key strengths?
Claude: Strong cash position of $273.1M representing 58% of total assets. Excellent liquidity with 7.41x current ratio and no long-term debt obligations. ChatGPT: Loss per share and net loss improved year over year, indicating some operating progress. Balance sheet leverage appears low with no reported long-term debt and 0.00x debt-to-equity.
What are the risks of investing in BHVN?
Claude: Absent revenue generation with no sales reported despite pharmaceutical sector classification. Operating cash burn of -$149.9M annually provides approximately 1.8 year runway at current rate. ChatGPT: No reported revenue means the business is not yet demonstrating commercial traction or recurring earnings power. Extremely high cash burn and deeply negative operating income suggest future capital needs if spending remains elevated.
What is BHVN's revenue and growth?
Biohaven Ltd. reported revenue of N/A.
Does BHVN pay dividends?
Biohaven Ltd. does not currently pay dividends.
Where can I find BHVN SEC filings?
Official SEC filings for Biohaven Ltd. (CIK: 0001935979) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BHVN's EPS?
Biohaven Ltd. has a diluted EPS of $-0.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BHVN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Biohaven Ltd. has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BHVN stock overvalued or undervalued?
Valuation metrics for BHVN: ROE of -100.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BHVN's AI grade for 2026?
Our dual AI analysis gives Biohaven Ltd. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BHVN's free cash flow?
Biohaven Ltd.'s operating cash flow is $-149.9M, with capital expenditures of $0.0.
How does BHVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -100.8% (avg: 15%), current ratio 7.41 (avg: 2).